High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Many classical tumor suppressor genes (TSG) were identified by delineation of bi‐allelic losses called homozygous deletions. To identify systematically homozygous deletions in laryngeal squamous cell carcinoma (LSCC) and to unravel novel putative tumor suppressor genes, we screened 10 LSCC cell lines using high resolution array comparative genomic hybridization (arrayCGH) and array based expression analysis. ArrayCGH identified altogether 113 regions harboring protein coding genes that showed strong reduction in copy number indicating a potential homozygous deletion. Out of the 113 candidate regions, 22 novel homozygous deletions that affected the coding sequences of 15 genes were confirmed by multiplexPCR. Three genes were homozygously lost in two cell lines: PCDH17/PCH68, PRR20, and PTPRD. For the 15 homozygously deleted genes, four showed statistically significant downregulation of expression in LSCC cell lines as compared with normal human laryngeal controls. These were ATG7 (1/10 cell line), ZMYND11 (BS69) (1/10 cell line), PCDH17/PCH68 (9/10 cell lines), and PTPRD (7/10 cell lines). Quantitative real‐time PCR was used to confirm the downregulation of the candidate genes in 10 expression array‐studied cell lines and an additional cohort of cell lines; statistical significant downregulation of PCDH17/PCH68 and PTPRD was observed. In line with this also Western blot analyses demonstrated a complete absence of the PCDH17 and PTPRD proteins. Thus, expression profiling confirmed recurrent alterations of two genes identified primarily by delineation of homozygous deletions. These were PCDH17/PCH68, the protocadherin gene, and the STAT3 inhibiting receptor protein tyrosine phosphatase gene PTPRD. These genes are good candidates for novel TSG in LSCC. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Several TSG, including CDKN2A, PTEN, SMARCB1, RB1, and TNFAIP3, were thus identified by the delineation of homozygous deletions (Kamb et al., 1994; Li et al., 1997; Versteege et al., 1998; Schmitz et al., 2009).”
Background
Cited by
A versatile drug delivery system targeting senescent cells
Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809355 · Cited by 339
“Of note, the three cell lines used, SK-MEL103, NCI-H226, and UT-SCC-42B, have an active retinoblastoma pathway (RB1-proficient; Ikediobi et al, 2006; Giefing et al, 2011; Massaro et al, 2017) and undergo senescence upon treatment with palbociclib (Fig 1B and Appendix Fig S1F).”
MethodProtocadherins at the Crossroad of Signaling Pathways
Pancho, A., Aerts, T., Mitsogiannis, M. D., & Seuntjens, E. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00117 · Cited by 189
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“Additionally, PTPRD is commonly epigenetically silenced through promoter hypermethylation in glioblastoma, HNSCC, lung and colon cancer (209), as well as in LSCC and HCC (205, 213).”
Background
Metadata
- Authors
- Giefing, M., Zemke, N., Brauze, D., Kostrzewska‐Poczekaj, M., Luczak, M., Szaumkessel, M., Pelinska, K., Kiwerska, K., Tönnies, H., Grenman, R., Figlerowicz, M., Siebert, R., Szyfter, K., & Jarmuz, M.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2010-12-07
- Volume
- 50
- Issue
- 3
- Pages
- 154-166
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2057016353
- Cited by
- 61
- References
- 2
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.